ATE304545T1 - Verfahren zur hemmung von tyrosinphosphatase 1b und/oder t-zellenprotein-tyrosinphosphatase und/oder anderen ptpasen mit einem asp-rest in position 48 - Google Patents
Verfahren zur hemmung von tyrosinphosphatase 1b und/oder t-zellenprotein-tyrosinphosphatase und/oder anderen ptpasen mit einem asp-rest in position 48Info
- Publication number
- ATE304545T1 ATE304545T1 AT02740410T AT02740410T ATE304545T1 AT E304545 T1 ATE304545 T1 AT E304545T1 AT 02740410 T AT02740410 T AT 02740410T AT 02740410 T AT02740410 T AT 02740410T AT E304545 T1 ATE304545 T1 AT E304545T1
- Authority
- AT
- Austria
- Prior art keywords
- tyrosine phosphatase
- ptpases
- protein tyrosine
- cell protein
- inhibiting
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200101022 | 2001-06-29 | ||
DKPA200200105 | 2002-01-21 | ||
PCT/DK2002/000425 WO2003002569A1 (en) | 2001-06-29 | 2002-06-25 | Method of inhibiting ptp 1b and/or t-cell ptp and/or other ptpases with an asp residue at position 48 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE304545T1 true ATE304545T1 (de) | 2005-09-15 |
Family
ID=26069043
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT02740410T ATE304545T1 (de) | 2001-06-29 | 2002-06-25 | Verfahren zur hemmung von tyrosinphosphatase 1b und/oder t-zellenprotein-tyrosinphosphatase und/oder anderen ptpasen mit einem asp-rest in position 48 |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1404682B1 (de) |
JP (1) | JP2004535451A (de) |
AT (1) | ATE304545T1 (de) |
DE (1) | DE60206174T2 (de) |
WO (1) | WO2003002569A1 (de) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003249865A1 (en) * | 2003-06-24 | 2005-01-21 | Actelion Pharmaceuticals Ltd | Pyrazolidinedione derivatives and their use as platelet aggregation inhibitors |
MX2011004258A (es) | 2008-10-22 | 2011-06-01 | Merck Sharp & Dohme | Derivados de bencimidazol ciclicos novedosos utiles como agentes anti-diabeticos. |
CA2741672A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
CA2786314A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
KR101668514B1 (ko) | 2011-02-25 | 2016-10-21 | 머크 샤프 앤드 돔 코포레이션 | 항당뇨병제로서 유용한 신규 시클릭 아자벤즈이미다졸 유도체 |
JP2015525782A (ja) | 2012-08-02 | 2015-09-07 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 抗糖尿病性三環式化合物 |
EP2900674B1 (de) | 2012-09-28 | 2017-05-31 | University of Washington through its Center for Commercialization | Verbindungen und verfahren zur vorbeugung, behandlung und/oder schutz vor haarzelltod |
RU2015140066A (ru) | 2013-02-22 | 2017-03-30 | Мерк Шарп И Доум Корп. | Противодиабетические бициклические соединения |
US9650375B2 (en) | 2013-03-14 | 2017-05-16 | Merck Sharp & Dohme Corp. | Indole derivatives useful as anti-diabetic agents |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
US10399994B2 (en) | 2015-02-06 | 2019-09-03 | University Of Washington | Compounds and methods for preventing or treating sensory hair cell death |
WO2018106518A1 (en) | 2016-12-06 | 2018-06-14 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
US10968232B2 (en) | 2016-12-20 | 2021-04-06 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999046267A1 (en) * | 1998-03-12 | 1999-09-16 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (ptpases) |
WO1999046237A1 (en) * | 1998-03-12 | 1999-09-16 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases |
-
2002
- 2002-06-25 DE DE60206174T patent/DE60206174T2/de not_active Expired - Fee Related
- 2002-06-25 JP JP2003508950A patent/JP2004535451A/ja not_active Withdrawn
- 2002-06-25 EP EP02740410A patent/EP1404682B1/de not_active Expired - Lifetime
- 2002-06-25 WO PCT/DK2002/000425 patent/WO2003002569A1/en active IP Right Grant
- 2002-06-25 AT AT02740410T patent/ATE304545T1/de not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
WO2003002569A1 (en) | 2003-01-09 |
DE60206174D1 (de) | 2005-10-20 |
DE60206174T2 (de) | 2006-06-22 |
EP1404682B1 (de) | 2005-09-14 |
JP2004535451A (ja) | 2004-11-25 |
EP1404682A1 (de) | 2004-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE304545T1 (de) | Verfahren zur hemmung von tyrosinphosphatase 1b und/oder t-zellenprotein-tyrosinphosphatase und/oder anderen ptpasen mit einem asp-rest in position 48 | |
DE69905476T2 (de) | Phosphonsaürederivate als ptp-1b-inhibitoren | |
EA200501805A1 (ru) | Фармацевтическая композиция, содержащая ингибитор фермента дипептидилпептидазы | |
DE60234464D1 (de) | Zusammensetzungen und Verfahren zur selektiven Nukleinsäureisolierung | |
DE60327811D1 (de) | Sulfhydantoine als phosphatisostere zur verwendung als phosphatasehemmer bei der behandlung von krebs und autoimmunerkrankungen | |
ATE308880T1 (de) | Verfahren zur erhöhung der biologischen effektivität von zusammensetzungen zur pflanzenbehandlung | |
NO990855L (no) | Substituerte sykliske amin-metallprotease-inhibitorer | |
ATE451369T1 (de) | Piperidinopyrimidindipeptidylpeptidaseinhibitor n zur behandlung von diabetes | |
EA200000298A1 (ru) | Агонисты простагландинов и их применение для лечения заболеваний костей | |
DE69531753T2 (de) | Verbindungen zur Hemmung der Thrombin | |
BRPI9909660B8 (pt) | compostos inibidores de caspases, composição farmacêutica e uso de ditos compostos | |
BRPI0507972A (pt) | composto ,composição farmacêutica , uso de um composto, método para inibição da atividade proteolìtica de uma enzima de clivagem pós prolina e composição farmacêutica embalada | |
BRPI0407993B8 (pt) | compostos inibidores de p38 e composições farmacêuticas compreendendo os mesmos | |
DE69725354D1 (de) | Intermediate zur Herstellung von Thrombininhibitoren als Anticoagulantien | |
PT1163208E (pt) | Inibidores de caspase e as suas utilizacoes | |
ATE538651T1 (de) | Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit | |
SE9602263D0 (sv) | New amino acid derivatives | |
DE69821376D1 (de) | Verfahren zur proteinrückfaltung durch verwendung zwitterionischer wirkstoffe von niedrigem molekulargewicht | |
ATE383160T1 (de) | Phosphinsäurederivate, inhibitoren von beta- sekretase zur behandlung von alzheimer-krankheit | |
ATE311388T1 (de) | Pyrimidotriazine als phosphataseinhibitoren | |
BR9916255A (pt) | Composto, composição farmacêutica, uso de um composto, e, métodos de tratamento de uma condição em que se requer inibição de trombina e para a preparação de compostos | |
ATE538796T1 (de) | Piperidin- und pyrrolidin-beta-secretase-hemmer zur behandlung von alzheimer-krankheit | |
DE60329326D1 (de) | Tace inhibitoren | |
ATE479332T1 (de) | Verfahren zur hemmung der ethylenreaktionen von pflanzen | |
DE60103213D1 (de) | Verfahren zur Fest-Flüssig-Fraktionierung von Ölzusammensetzungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |